Subscribe

Glossary

Cytokines

Signals immune cells use to talk to each other. Several of them are the targets of the biggest drug classes in rheumatology, and not one of them is a disease outcome by itself.

Cytokines are how immune cells talk to each other, and several of them are drug targets, which is why their names turn up on prescriptions. Moving one of them in a study turns out to be fairly easy. Improving a disease is not, and the distance between those two results is most of what this page is about.

Quick answerCytokines are signals immune cells release to affect each other, and several are drug targets in rheumatology. Moving one isn't the same as improving a disease. One trial was done in 144 rheumatoid arthritis patients across three groups, where interleukin-6 fell in only one of them while daily pain fell in all three, with no group beating the others.
That trial is the cleanest example on this site of why the difference counts. Interleukin-6 production fell from 8.94 to 8.51, in the cognitive behavioral therapy group alone, at a P value of 0.02 for the group by time effect. The authors say so plainly: there was no interleukin-6 effect in the mindfulness group, which didn't support one of their main ideas. Meanwhile daily pain fell across all three groups with no group beating the others, so the cytokine and the symptom moved independently of each other.

What they are

Cytokines are small proteins that immune cells release to affect other cells, so they're the messaging system of the immune response. They're also why a local event can start a reaction that spreads across a whole body. Some of them drive inflammation and some of them hold it back.

Four names come up most often in rheumatology, and those are tumor necrosis factor, usually shortened to TNF, and interleukin-1, interleukin-6, and interleukin-17. All four turn up in the names of major drug classes, which is why a patient ends up reading about a signaling protein at all. A drug that blocks one gets described by what it blocks.

That's the useful part of knowing the word. The less useful part is how the word gets used, because it sells almost everything aimed at people with an inflammatory disease. Separating those two uses is the subject of most of this page.

Why a cytokine result isn't a disease result

One trial in our sources shows this better than any argument could. It was done in 144 rheumatoid arthritis patients and compared three things: cognitive behavioral therapy for pain, mindfulness meditation with emotion regulation, and education alone. It measured interleukin-6 production, and it measured daily pain and several other outcomes too.

Interleukin-6 fell from 8.94 to 8.51 in the cognitive behavioral therapy group only, at a P value of 0.02 for the group by time effect. The authors say plainly what that meant: there was no interleukin-6 effect in the mindfulness group, which didn't support one of the study's main ideas. Meanwhile daily pain fell from 33.50 to 28.63 across the trial, with no group beating the others at all.

So look at what happened in one trial, in the same patients. The cytokine moved in one group and the symptom moved in all of them, which means those two results point in different directions about which treatment worked. That's what it looks like when a mechanism marker and a clinical outcome come apart.

Common misconceptions.

Myth. Lowering a cytokine means my disease is improving.

Reality. Those are two claims, and only one of them usually gets tested. One trial was done in 144 rheumatoid arthritis patients, where interleukin-6 fell in one group only while daily pain fell in all three groups with no group beating the others. So the cytokine and the symptom moved independently. When something is described as lowering inflammatory signals, ask whether a disease outcome moved too.

Myth. A supplement that reduces a cytokine is treating my arthritis.

Reality. It's producing a lab result, which is the easier of the two things to produce. The largest nutrition review here reports one such finding, where synbiotics lowered interleukin-17 in psoriatic arthritis, and it reports no disease result to put beside it. So a cytokine change with no outcome attached is a reason to keep studying something rather than a reason to take it.

Myth. Cytokine levels tell my rheumatologist how I'm doing.

Reality. They mostly don't get measured in routine care, which surprises people who have read about them. Disease activity gets followed three ways instead, through joint counts, an inflammation marker like CRP, and your own rating. This site holds no source on using single cytokine measurements to follow disease, so what such a result would mean is a question for whoever ordered it.

Myth. If cytokines cause the disease, blocking one should fix it.

Reality. Blocking them really is the basis of the strongest drug classes here, and the 2024 international recommendations for Still's disease are built around blocking interleukin-1 and interleukin-6. What the evidence doesn't support is the step backward, where something that nudges a cytokine down gets treated as doing what those drugs do. Three things make the difference: the target, the dose, and how fully it's blocked.

Related terms.

  • Interleukin-6, the cytokine with the most data on this site.
  • TNF-alpha, the first of them to become a major drug target.
  • Inflammation, and the difference between the kind you can measure and the kind you have.
  • DAS28, the disease outcome that lifestyle studies keep failing to move.

References.

  1. Zautra A; Davis M; Reich J et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression.. Journal of Consulting and Clinical Psychology. 2008;76:408-421. 10.1037/0022-006X.76.3.408Randomised controlled trial
  2. Irwin M; Olmstead R; Carroll J. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biological Psychiatry. 2016;80:40-52. 10.1016/j.biopsych.2015.05.014Systematic review and meta-analysis of 72 cohort studies and experimental sleep deprivation studies
  3. Van den Bruel K; Kulyk M; Neerinckx B et al. Nutrition and diet in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: a systematic review. Frontiers in medicine. 2025;12:1655165. 10.3389/fmed.2025.1655165SR
  4. Fautrel B; Mitrovic S; De Matteis A et al. EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Annals of the Rheumatic Diseases. 2024;83:1614-1627. 10.1136/ard-2024-225851International guideline

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.